Chemistry:Tofenacin
From HandWiki
Short description: SNRI antidepressant medication
 | |
| Clinical data | |
|---|---|
| Trade names | Elamol, Tofacine, Tofalin |
| Other names | tofenacin hydrochloride (USAN US) |
| Routes of administration | By mouth |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C17H21NO |
| Molar mass | 255.361 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Tofenacin is an antidepressant drug with a tricyclic-like structure which was developed and marketed in the United Kingdom and Italy in 1971 and 1981, respectively, by Brocades-Stheeman & Pharmacia (now part of Astellas Pharma).[1][2][3] It acts as a serotonin-norepinephrine reuptake inhibitor,[4] and based on its close relation to orphenadrine, may also possess anticholinergic and antihistamine properties. Tofenacin is also the major active metabolite of orphenadrine and likely plays a role in its beneficial effects against depressive symptoms seen in Parkinson's disease patients.[5][6]
See also
References
- ↑ Index Nominum 2000: International Drug Directory. Taylor & Francis US. 2000. p. 1041. ISBN 978-3-88763-075-1. https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA1041. Retrieved 19 May 2012.
- ↑ Dictionary of organic compounds: Chemical Abstracts Service registry number index. CRC Press. 1996. p. 6074. ISBN 978-0-412-54090-5. https://books.google.com/books?id=2Ggj1SncMBEC&pg=PA6074. Retrieved 19 May 2012.
- ↑ Pharmaceutical Manufacturing Encyclopedia (3rd ed.). Elsevier. 2013-01-15. p. 3268. ISBN 978-0-8155-1526-5. https://books.google.com/books?id=TIu28TH_iAYC&pg=PA3268. Retrieved 19 May 2012.
- ↑ "Non-Tricyclic Antidepressants". Progress in Medicinal Chemistry. Elsevier. 1 January 1978. p. 284. ISBN 978-0-7204-0655-9. https://books.google.com/books?id=YN9YWk4T4fwC&pg=PA284. Retrieved 19 May 2012.
- ↑ "A comparative trial of orphenadrine and tofenacin in the control of depression and extrapyramidal side-effects associated with fluphenazine decanoate therapy". The Journal of International Medical Research 4 (6): 435–440. 1976. doi:10.1177/030006057600400610. PMID 800383.
- ↑ "Residual neuroleptic-induced parkinsonian symptoms in schizophrenia. A naturalistic study with orphenadrine". Pharmacopsychiatry 22 (6): 246–249. November 1989. doi:10.1055/s-2007-1014608. PMID 2616635.
 |  |
